<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Res</journal-id><journal-id journal-id-type="publisher-id">cvrese</journal-id><journal-id journal-id-type="hwp">cardiovascres</journal-id><journal-title-group><journal-title>Cardiovascular Research</journal-title></journal-title-group><issn pub-type="ppub">0008-6363</issn><issn pub-type="epub">1755-3245</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19168855</article-id><article-id pub-id-type="pmc">2675930</article-id><article-id pub-id-type="doi">10.1093/cvr/cvp001</article-id><article-id pub-id-type="publisher-id">cvp001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group><series-title>Editor's Choice</series-title></article-categories><title-group><article-title>Protein kinase C in heart failure: a therapeutic target?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Palaniyandi</surname><given-names>Suresh Selvaraj</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Lihan</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Julio Cesar Batista</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mochly-Rosen</surname><given-names>Daria</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Department of Chemical and Systems Biology</addr-line>, <institution>Stanford University School of Medicine</institution>, <addr-line>CCSR, Rm 3145A, 269 Campus Drive, Stanford, CA 94305-5174</addr-line>, <country>USA</country></aff><aff id="af2"><label>2</label><addr-line>School of Physical Education and Sport</addr-line>, <institution>University of S&#x000e3;o Paulo</institution>, <addr-line>SP 05508-900</addr-line>, <country>Brazil</country></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Tel: <phone>+1 650 725 7720</phone>; fax: <fax>+1 650 723 2253</fax>. <italic>E-mail address</italic>: <email>mochly@stanford.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>5</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>24</day><month>1</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>1</month><year>2009</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>82</volume><issue>2</issue><fpage>229</fpage><lpage>239</lpage><history><date date-type="received"><day>26</day><month>9</month><year>2008</year></date><date date-type="rev-recd"><day>13</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Published on behalf of the European Society of Cardiology. All rights reserved. &#x000a9; The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.</copyright-statement><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><license-p>The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.</license-p></license></permissions><abstract><p>Heart failure (HF) afflicts about 5 million people and causes 300 000 deaths a year in the United States alone. An integral part of the pathogenesis of HF is cardiac remodelling, and the signalling events that regulate it are a subject of intense research. Cardiac remodelling is the sum of responses of the heart to causes of HF, such as ischaemia, myocardial infarction, volume and pressure overload, infection, inflammation, and mechanical injury. These responses, including cardiomyocyte hypertrophy, myocardial fibrosis, and inflammation, involve numerous cellular and structural changes and ultimately result in a progressive decline in cardiac performance. Pharmacological and genetic manipulation of cultured heart cells and animal models of HF and the analysis of cardiac samples from patients with HF are all used to identify the molecular and cellular mechanisms leading to the disease. Protein kinase C (PKC) isozymes, a family of serine&#x02013;threonine protein kinase enzymes, were found to regulate a number of cardiac responses, including those associated with HF. In this review, we describe the PKC isozymes that play critical roles in specific aspects of cardiac remodelling and dysfunction in HF.</p></abstract><kwd-group><title>Keywords</title><kwd>Protein kinase C</kwd><kwd>Heart failure</kwd><kwd>Cardiac remodeling</kwd><kwd>Hypertrophy</kwd><kwd>Fibrosis and inflammation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>primary-review-time</meta-name><meta-value><bold>Time for primary review: 21 days</bold></meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><label>1.</label><title>Protein kinase C: an introduction</title><p>Protein kinase C (PKC) is a group of closely related serine&#x02013;threonine protein kinases, further classified as (1) the classical PKCs (&#x003b1;, &#x003b2;I, &#x003b2;II, and &#x003b3;), the diacylglycerol (DAG)-, and calcium-dependent enzymes, (2) the novel PKCs (&#x003b4;, &#x003f5;, &#x003b8;, and &#x003b7;), which require DAG, but not calcium, for activity, and (3) the atypical PKCs (&#x003b6;, &#x003bb;), which are not stimulated by DAG or calcium, but are stimulated by other lipid-derived second messengers.</p><sec id="s1a"><label>1.1</label><title>Protein kinase C in the normal and diseased myocardium</title><p>PKC isozymes are expressed in all tissues. mRNA expression of &#x003b1;, &#x003b4;, &#x003f5;, &#x003b7;, and &#x003b6;PKCs is found in rat cultured cardiomyocytes.<sup><xref ref-type="bibr" rid="CVP001C1">1</xref>,<xref ref-type="bibr" rid="CVP001C2">2</xref></sup> Abundant expression of both &#x003b2;I and &#x003b2;IIPKC in human and rat cardiomyocytes has also been reported,<sup><xref ref-type="bibr" rid="CVP001C3">3</xref>&#x02013;<xref ref-type="bibr" rid="CVP001C6">6</xref></sup> whereas the mouse myocardium expresses low levels of these &#x003b2;PKCs.<sup><xref ref-type="bibr" rid="CVP001C7">7</xref></sup> Further species-specific differences in the expression of &#x003b7;, &#x003b8;, and &#x003f5;PKC were also reported.<sup><xref ref-type="bibr" rid="CVP001C8">8</xref></sup> Therefore, the interpretation of animal studies must be done with caution as species to species variation in PKC isozyme expression is substantial. Western blot analyses of human cardiac tissue using polyclonal antibodies (PKC-&#x003b1;, -&#x003b2;I, -&#x003b2;II -&#x003b5;, -&#x003b4;,-&#x003b3;, and -&#x003b7;) or monoclonal antibodies (PKC-&#x003bb;, -&#x003bc;, and -&#x003b8;) demonstrated the presence of these isozymes in human heart tissue.<sup><xref ref-type="bibr" rid="CVP001C4">4</xref></sup> This study also demonstrated differences in the distribution of PKC isozymes between the atria and ventricles. The calcium-dependent isozymes, &#x003b1;, &#x003b2;I, and &#x003b2;IIPKC, reside predominantly in the ventricle, whereas &#x003b4; and &#x003b6;PKC are mainly expressed in the atria and &#x003b5; and &#x003bb;PKC are evenly distributed in both atria and ventricles.</p><p>PKC isozymes are involved in a variety of chronic cardiac diseases<sup><xref ref-type="bibr" rid="CVP001C9">9</xref></sup> as well as in acute cardiac injuries and preconditioning.<sup><xref ref-type="bibr" rid="CVP001C10">10</xref></sup> We and others have demonstrated that select PKC isozymes contribute to heart failure (HF).<sup><xref ref-type="bibr" rid="CVP001C9">9</xref>,<xref ref-type="bibr" rid="CVP001C11">11</xref>&#x02013;<xref ref-type="bibr" rid="CVP001C16">16</xref></sup> Isozyme-selective tools that were generated in the past few years, including pharmacological peptide regulators (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP001F1">1</xref></italic>) and use of genetic manipulation and RNAi, demonstrated that the same isozyme may mediate different functions in acute vs. chronic heart diseases. For example, &#x003b5;PKC activation prior to MI is protective,<sup><xref ref-type="bibr" rid="CVP001C17">17</xref></sup> whereas in hypertension-induced HF &#x003b5;PKC activation is detrimental.<sup><xref ref-type="bibr" rid="CVP001C15">15</xref></sup> Here we review the role of PKC isozymes in cardiac remodelling and HF.</p><fig id="CVP001F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Protein kinase C peptide modulators. (<italic>A</italic>) Inactive protein kinase C (gray) undergoes a conformational change exposing both the RACK-binding site and the active site when diacylglycerol (DG) or PMA are elevated. Active protein kinase C (blue) binds to its RACK (red), anchoring the activated isozyme near its substrate (green). Phosphorylation (P) of that substrate leads to the physiological responses of that isozyme. (<italic>B</italic>) Alternatively, a peptide that mimics the RACK-binding site, pseudo-RACK (&#x003a8;RACK, yellow) can also cause these conformational changes. &#x003a8;RACK binds to protein kinase C with a lower affinity than the intact RACK and thus does not always occupy the RACK-binding site on the enzyme. During the time that the peptide is not bound, the activated enzyme may bind to its RACK (red), resulting in anchoring of the activated isozyme near its substrate (green) followed by substrate phosphorylation (P) and physiological responses. This process is isozyme-specific. (<italic>C</italic>) A peptide corresponding to the RACK-biding site on protein kinase C (orange) inhibits translocation and function of its corresponding isozyme. The translocation inhibitor peptide binds to the RACK and blocks binding of the activated isozyme to that RACK. Therefore, the physiological responses mediated by that isozyme are blocked.</p></caption><graphic xlink:href="cvp00101"/></fig></sec></sec><sec id="s2"><label>2.</label><title>Heart failure: an introduction</title><p>HF is a clinical syndrome characterized by impaired ability of the left ventricle to fill or eject blood.<sup><xref ref-type="bibr" rid="CVP001C18">18</xref></sup> Currently, the life-time risk to develop HF after the age of 40 is &#x0223c;20% for men or women.<sup><xref ref-type="bibr" rid="CVP001C19">19</xref></sup> The aetiology of HF is diverse and includes ischaemia, hypertension, idiopathic cardiomyopathy, bacterial endocarditis, congenital cardiovascular defects, and valvular diseases. However, the most common aetiologies of HF are coronary artery disease and myocardial infarction (MI);<sup><xref ref-type="bibr" rid="CVP001C20">20</xref></sup> each year, about one million people suffer from acute MI and within 6 years, HF will disable about 300 000 of these patients.<sup><xref ref-type="bibr" rid="CVP001C19">19</xref></sup></p><sec id="s2a"><label>2.1</label><title>Cardiac remodelling</title><p>Cardiac remodeling is an early and progressive response of the heart to insults, such as ischaemia, volume and pressure overload, infection, inflammation, mechanical injury, and stimulation by cytokines and enzymes. Depending on the extent of cardiomyocyte loss by these insults, fibroblast proliferation and collagen secretion, namely fibrosis, is triggered to maintain the shape and structure of the myocardium. Injuries to coronary vasculature, stimulation by stress factors, and fibrosis also result in changes in structure and function of blood vessels. Infiltration of inflammatory cells into the jeopardized myocardium leads to continuous release of cytokines, chemokines, enzymes, and growth factors, which further contribute to the remodelling process. Therefore, a better understanding of the cellular and molecular basis of cardiac remodelling events, including adaptive and maladaptive hypertrophy, perivascular and interstitial fibrosis, and inflammation, will further clarify the pathogenesis of HF.</p></sec></sec><sec id="s3"><label>3.</label><title>Cardiac hypertrophy: adaptive and maladaptive responses</title><p>Adaptive cardiac hypertrophy is characterized by an increase in heart mass and wall thickening due to an increase in cardiac myocyte size and protein synthesis, and is associated with improved cardiac function.<sup><xref ref-type="bibr" rid="CVP001C21">21</xref></sup> If cardiac overload continues, a transition from adaptive to maladaptive hypertrophy takes place. This is associated with left ventricle dilation, a decrease in contractile elements, and reduced cardiac output.<sup><xref ref-type="bibr" rid="CVP001C21">21</xref></sup> The use of culture studies, animal models, and human samples with HF provided insight into the role of PKC in this pathology.</p><sec id="s3a"><label>3.1</label><title>Protein kinase C isozymes in cardiomyocyte hypertrophy in cell culture models</title><p>Neonatal cardiomyocytes are commonly used to study hypertrophic signalling. Whether this model represents developmental hypertrophy only or whether it also provides an appropriate model of pathological hypertrophy is debated. However, because cardiac remodelling activates many of the cardiac embryonic developmental programs, this culture model may provide an insight into HF. A variety of stimulants, such as phorbol myristate acetate (PMA), angiotensin-II (AngII), phenylephrine (PE), and endothelin-1 (ET1), are used to induce hypertrophy in culture (<italic>Table <xref ref-type="table" rid="CVP001TB1">1</xref></italic>). PMA, which activates both conventional and novel PKC isozymes, or transfection of either wild-type (WT) or dominant-negative (DN) &#x003b1;PKC mutant demonstrated that &#x003b1;PKC is both necessary and sufficient to induce certain features of cardiomyocyte hypertrophy including increases in protein synthesis, the protein-to-DNA ratio, and cell surface area.<sup><xref ref-type="bibr" rid="CVP001C22">22</xref></sup> Further, &#x003b1;PKC antisense treatment reduced PE-induced increases in &#x003b1;-actin mRNA and atrial natriuretic peptide (ANP) secretion, but not PE-induced &#x003b2;-myosin heavy chain, ANP, or B-type natriuretic peptide (BNP) gene expression,<sup><xref ref-type="bibr" rid="CVP001C23">23</xref></sup> therefore causing a loss of only some to the pathological hypertrophic markers. In other studies, overexpression of &#x003b1;PKC increased cell surface area, [<sup>3</sup>H]-leucine incorporation, and mRNA levels of ANP,<sup><xref ref-type="bibr" rid="CVP001C24">24</xref></sup> together indicating that &#x003b1;PKC activation induced cardiomyocyte hypertrophy in cultured cardiomyocytes. We found that &#x003b2;I and &#x003b2;IIPKC are required for PMA-induced cardiomyocyte hypertrophy.<sup><xref ref-type="bibr" rid="CVP001C25">25</xref></sup> Later, we substantiated that RBCK-1 (RBCC protein that interacts with &#x003b2;IPKC) is essential for PE-induced cardiomyocyte hypertrophy.<sup><xref ref-type="bibr" rid="CVP001C26">26</xref></sup> Overexpression of RBCK1 increased the cardiac myocyte cell surface by 50% in the absence of PE treatment and the &#x003b2;I- and &#x003b2;IIPKC-specific peptide inhibitors prevented that effect.<sup><xref ref-type="bibr" rid="CVP001C26">26</xref></sup> A role for &#x003b5;PKC has also been suggested; treatment with &#x003b5;PKC antisense reduced myotrophin-induced stimulation of protein synthesis in neonatal myocytes.<sup><xref ref-type="bibr" rid="CVP001C27">27</xref></sup> This study also found that &#x003b4; and &#x003b6;PKC are not involved in this process. Therefore, at least four PKC isozymes, &#x003b1;, &#x003b2;I, &#x003b2;II, and &#x003b5; induce hypertrophy in neonatal cardiac myocytes.</p><table-wrap id="CVP001TB1" position="float"><label>Table&#x000a0;1</label><caption><p>The role of individual protein kinase C isozymes in cardiac remodelling and heart failure</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Model</th><th align="left" rowspan="1" colspan="1">Cardiac phenotype</th><th align="left" rowspan="1" colspan="1">PKC isozyme</th><th align="left" rowspan="1" colspan="1">Stimulus/treatment</th><th align="left" rowspan="1" colspan="1">Main response</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Streptozotocin-induced diabetic rats</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">cPKCs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Increased cardiac &#x000df;IIPKC activity</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C86">86</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Transgenic mice</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">&#x003b5;PKC</td><td rowspan="1" colspan="1">Cardiac-specific expression of &#x003b5;PKC inhibitor, &#x003b5;V1</td><td rowspan="1" colspan="1">Lethal dilated cardiomyopathy</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C36">36</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Transgenic mice</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">&#x003b5;PKC</td><td rowspan="1" colspan="1">Cardiac-specific expression of &#x003b5;PKC activator, &#x003c8;&#x003b5;RACK</td><td rowspan="1" colspan="1">Concentric cardiac hypertrophy</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C36">36</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Transgenic mice</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">&#x003b5;PKC</td><td rowspan="1" colspan="1">Over-expression constitutively active &#x003b5;PKC</td><td rowspan="1" colspan="1">Concentric cardiac hypertrophy</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C87">87</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Transgenic mice</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">cPKCs and nPKCs</td><td rowspan="1" colspan="1">Active calcineurin over-expression</td><td rowspan="1" colspan="1">Increased cardiac &#x003b1; and &#x003b2;PKC translocation</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C88">88</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Pressure-overload aortic banding rats</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">cPKCs and nPKCs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Increased cardiac &#x003b2;IPKC, &#x003b2;IIPKC, &#x003b5;PKC, and &#x003b8;PKC translocation</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C89">89</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Transgenic mice</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">&#x003b2;IIPKC and &#x003b5;PKC</td><td rowspan="1" colspan="1">Over-expression constitutively active &#x003b5;PKC</td><td rowspan="1" colspan="1">Pathological cardiac hypertrophy</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C90">90</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Adult rat ventricle myocyte</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">&#x003b5;PKC</td><td rowspan="1" colspan="1">Pharmacological: &#x003b5;V1-2 (specific &#x003b5;PKC isozyme inhibitor)</td><td rowspan="1" colspan="1">Attenuated isoproterenol-induced apoptosis</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C91">91</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Dahl salt-sensitive hypertensive rats</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">cPKCs and nPKCs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Increased cardiac &#x003b5;PKC levels in compensatory stage and &#x003b2;IIPKC levels during cardiac dysfunction</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C14">14</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Pressure-overload aortic banding rats</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">&#x003b1;PKC and &#x003b4;PKC</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Increased cardiac levels of &#x003b1;PKC and &#x003b4;PKC</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C92">92</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Adult guinea pig heart (<italic>ex vivo</italic>)</td><td rowspan="1" colspan="1">Hypertrophy</td><td rowspan="1" colspan="1">cPKCs and nPKCs</td><td rowspan="1" colspan="1">Perfusion with angiotensin II</td><td rowspan="1" colspan="1">Increased cardiac &#x003b1;PKC, &#x003b2;IIPKC, and &#x003b3;PKC</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C93">93</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Dahl Salt hypertensive rats</td><td rowspan="1" colspan="1">Hypertrophy/heart failure</td><td rowspan="1" colspan="1">cPKCs, nPKCs, and aPKCs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Increased cardiac levels of cPKC, nPKC, and aPKC</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C94">94</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Pressure-overload heart failure rats</td><td rowspan="1" colspan="1">Hypertrophy/heart failure</td><td rowspan="1" colspan="1">&#x003b1;PKC and &#x003b5;PKC</td><td rowspan="1" colspan="1">Sustained treatment with ACE inhibitor</td><td rowspan="1" colspan="1">ACE inhibitor attenuates increased &#x003b1;PKC and &#x003b5;PKC translocation</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C95">95</xref></sup></td></tr><tr><td rowspan="1" colspan="1">&#x003b2;IIPKC transgenic mice</td><td rowspan="1" colspan="1">Hypertrophy/heart Failure</td><td rowspan="1" colspan="1">&#x003b2;IIPKC</td><td rowspan="1" colspan="1">Cardiac-specific &#x003b2;IIPKC over-expression</td><td rowspan="1" colspan="1">Pathological cardiac hypertrophy</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C32">32</xref></sup></td></tr><tr><td rowspan="1" colspan="1">&#x003b1;PKC transgenic mice</td><td rowspan="1" colspan="1">Hypertrophy/heart failure</td><td rowspan="1" colspan="1">&#x003b1;PKC</td><td rowspan="1" colspan="1">Wild-type and dominant negative &#x003b1;PKC expression</td><td rowspan="1" colspan="1">Increased contractility and cardioprotection</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C29">29</xref>,<xref ref-type="bibr" rid="CVP001C96">96</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Human end-stage dilated or ischaemic cardiomyopathy</td><td rowspan="1" colspan="1">Heart failure</td><td rowspan="1" colspan="1">cPKCs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Increased cardiac &#x003b2;PKC activity</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C3">3</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Human end-stage Dilated cardiomyopathy</td><td rowspan="1" colspan="1">Heart failure</td><td rowspan="1" colspan="1">cPKCs and nPKCs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Increased cardiac &#x003b2;IIPKC levels</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C4">4</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Dahl Salt hypertensive rats</td><td rowspan="1" colspan="1">Heart failure</td><td rowspan="1" colspan="1">cPKCs and nPKCs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Increased cardiac &#x003b2;IPKC, &#x003b2;IIPKC levels, and translocation</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C14">14</xref></sup></td></tr><tr><td rowspan="1" colspan="1">MLP transgenic mice</td><td rowspan="1" colspan="1">Heart failure</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ro-31-8220 (cPKC and &#x003b5;PKC inhibitors)</td><td rowspan="1" colspan="1">PKC inhibition reverted cardiac hypertrophy</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C34">34</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Dahl Salt hypertensive rats</td><td rowspan="1" colspan="1">Fibrosis/heart failure</td><td rowspan="1" colspan="1">&#x003b5;PKC</td><td rowspan="1" colspan="1">Sustained treatment with &#x003b5;V1-2 (specific &#x003b5;PKC inhibitor)</td><td rowspan="1" colspan="1">Decreased cardiac fibrosis</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C15">15</xref></sup></td></tr><tr><td rowspan="1" colspan="1">&#x003b2;IIPKC transgenic mice</td><td rowspan="1" colspan="1">Hypertrophy/fibrosis</td><td rowspan="1" colspan="1">&#x003b2;IIPKC</td><td rowspan="1" colspan="1">Cardiac-specific over-expression of &#x003b2;IIPKC</td><td rowspan="1" colspan="1">Pathological cardiac hypertrophy and fibrosis</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C11">11</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Pressure-overload aortic banding mice</td><td rowspan="1" colspan="1">Fibrosis</td><td rowspan="1" colspan="1">&#x003b4;PKC and &#x003b5;PKC</td><td rowspan="1" colspan="1">&#x003b5;PKC knock-out mouse</td><td rowspan="1" colspan="1">Increased fibrosis</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C54">54</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Neonatal rat cardiac fibroblast</td><td rowspan="1" colspan="1">Fibroblast proliferation</td><td rowspan="1" colspan="1">&#x003b4;PKC and &#x003b6;PKC</td><td rowspan="1" colspan="1">TGF&#x003b2;1 and isozyme-specific inhibitors</td><td rowspan="1" colspan="1">Stimulated cardiac fibroblast proliferation</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C39">39</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Neonatal rat cardiac fibroblast</td><td rowspan="1" colspan="1">Fibroblast proliferation</td><td rowspan="1" colspan="1">cPKC, nPKC, and aPKC</td><td rowspan="1" colspan="1">Endothelin-1</td><td rowspan="1" colspan="1">Increased cardiac fibroblast proliferation</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C49">49</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Adult rat cardiac fibroblast</td><td rowspan="1" colspan="1">Fibroblast proliferation</td><td rowspan="1" colspan="1">&#x003b4;PKC</td><td rowspan="1" colspan="1">Angiotensin II</td><td rowspan="1" colspan="1">Increased &#x003b4;PKC and fibroblast proliferation</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C97">97</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Adult rat cardiac fibroblast</td><td rowspan="1" colspan="1">Collagen synthesis</td><td rowspan="1" colspan="1">cPKCs and nPKC</td><td rowspan="1" colspan="1">Mechanical load and non-specific PKC inhibitor (RO-31-8220)</td><td rowspan="1" colspan="1">Non-specific PKC inhibition and decreased collagen synthesis</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C98">98</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Myocardial infarction-induced heart failure rats</td><td rowspan="1" colspan="1">Fibroblast proliferation</td><td rowspan="1" colspan="1">&#x003b1;PKC, &#x003b2;IPKC, and &#x003b2;IIPKC</td><td rowspan="1" colspan="1">Non-specific PKC inhibitor (LY333531)</td><td rowspan="1" colspan="1">Decreased fibrosis and TGF&#x003b2;1 expression</td><td rowspan="1" colspan="1"><sup><xref ref-type="bibr" rid="CVP001C12">12</xref></sup></td></tr></tbody></table><table-wrap-foot><fn><p>PKC, protein kinase C.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><label>3.2</label><title>Protein kinase C in cardiac hypertrophy of animal models</title><p>&#x003b1;PKC expression and activity were unaltered in early HF but were up-regulated in two distinct rat models of end-stage HF.<sup><xref ref-type="bibr" rid="CVP001C28">28</xref></sup> Depletion of myocardial &#x003b1;PKC by gene knock-out increased myocardial contractility, whereas transgenic overexpression of &#x003b1;PKC led to marked ventricular dysfunction and alterations in Ca<sup>2+</sup> homeostasis.<sup><xref ref-type="bibr" rid="CVP001C29">29</xref></sup> Phosphorylation studies suggest that &#x003b1;PKC depresses myofilament contractility through phosphorylation of cTnI and/or cTnT.<sup><xref ref-type="bibr" rid="CVP001C30">30</xref></sup> Skinned left-ventricular myocytes isolated from rats subjected to chronic (8&#x02013;9 months) pressure overload or MI-induced HF in rats supported these conclusions; myofilament function is severely depressed in these experimental HF models.<sup><xref ref-type="bibr" rid="CVP001C28">28</xref></sup></p><p>In an earlier study, &#x003b2;PKC levels were elevated in hypertension-induced HF rats.<sup><xref ref-type="bibr" rid="CVP001C14">14</xref></sup> Treatment with angiotensin-receptor blocker improved cardiac function and decreased &#x003b2;PKC activation and levels.<sup><xref ref-type="bibr" rid="CVP001C14">14</xref></sup> In a recent study, we found that a selective inhibition of &#x003b2;IIPKC improved cardiac function and calcium handling in rats with post-MI HF, and improved function and prolonged the life span of rats with hypertension-induced HF.<sup><xref ref-type="bibr" rid="CVP001C31">31</xref></sup> In addition to reducing mortality, selective and sustained inhibition of &#x003b2;IIPKC by &#x003b2;IIV5-3 (a selective inhibitor of &#x003b2;IIPKC<sup><xref ref-type="bibr" rid="CVP001C25">25</xref></sup>) in rats with post-MI HF improved cardiac function compared with that prior to treatment initiation.<sup><xref ref-type="bibr" rid="CVP001C31">31</xref></sup> The beneficial effect was associated with enhanced calcium handling and normalization of the levels and phosphorylation of SERCA2, NCX, and troponin I.<sup><xref ref-type="bibr" rid="CVP001C31">31</xref></sup> Further, the reduction in cardiomyocyte width, HW/BW, and increased fractional shortening following &#x003b2;IIV5-3 treatment in rats with end-stage pathological hypertrophy were observed, thereby indicating that &#x003b2;IIPKC activation is a critical mediator of cardiac hypertrophy in rats (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP001F2">2</xref></italic>).</p><fig id="CVP001F2" position="float"><label>Figure&#x000a0;2</label><caption><p>Protein kinase C isozymes are closely involved with different remodelling events in myocardial infarction induced-heart failure. Heart failure progression is noticeably characterized by cardiac remodelling, whereas specific protein kinase C isozyme plays a crucial role in this time-related event. Cardiomyocyte death, inflammation, cardiac hypertrophy, and fibrosis are directly regulated by specific protein kinase C isozymes such as &#x003b1;, &#x003b2;II, &#x003b4;, and &#x003b5; protein kinase C as depicted in the figure. The TUNEL staining image is from Murriel <italic>et al</italic>. (2004)<sup><xref ref-type="bibr" rid="CVP001C33">33</xref></sup> and the hypertrophy image from <uri xlink:type="simple" xlink:href="www.ipmc.cnrs.fr">www.ipmc.cnrs.fr</uri>.</p></caption><graphic xlink:href="cvp00102"/></fig><p>Although the basal level of &#x003b2;PKC in the hearts of adult mice is low,<sup><xref ref-type="bibr" rid="CVP001C13">13</xref></sup> a number of reports suggest that &#x003b2;PKC is an important isozyme in cardiac diseases in mice, as well.<sup><xref ref-type="bibr" rid="CVP001C11">11</xref>,<xref ref-type="bibr" rid="CVP001C32">32</xref></sup> Targeted over-expression of &#x003b2;IIPKC in mice resulted in cardiac hypertrophy with myocardial dysfunction similar to that of HF.<sup><xref ref-type="bibr" rid="CVP001C11">11</xref></sup> Over-expression of activated &#x003b2;IIPKC in neonatal mice is fatal and, in the case of adult mice, it induces hypertrophy and myocardial dysfunction.<sup><xref ref-type="bibr" rid="CVP001C32">32</xref></sup> Pharmacological inhibition of &#x003b1; and &#x003b2;PKC by Ro-32-0432 improved myocardial contractility and left-ventricular developed pressure in mouse hearts.<sup><xref ref-type="bibr" rid="CVP001C34">34</xref></sup> In contrast to these observations, another study using &#x003b2;PKC knockout mice demonstrated no role for &#x003b2;PKC in HF development.<sup><xref ref-type="bibr" rid="CVP001C35">35</xref></sup> Hence the role of &#x003b2;PKC in cardiac hypertrophy in mice using genetic manipulation is controversial.</p><p>Transgenic mice that express &#x003b5; or &#x003b4;PKC activator or inhibitor peptides only postnatally and only in cardiac myocytes (using the &#x003b1;MHC promoter)<sup><xref ref-type="bibr" rid="CVP001C36">36</xref></sup> revealed potential redundant roles for these enzymes in cardiac hypertrophy. Mice expressing the &#x003b5;PKC-selective inhibitor, &#x003b5;V1, developed dilated eccentric cardiomyopathy and HF, an effect associated with a 10% increase in myocyte size when compared with the non-transgenic mice. Transgenic mice expressing the &#x003b5;PKC-selective activator, &#x003c8;&#x003b5;RACK, exhibited normal cardiac function, increased cardiac muscle mass (concentric hypertrophy) (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP001F2">2</xref></italic>), and had no increase in fibrosis. However, upon examination of cardiac myocyte cell size, it was found that myocytes were 10% smaller (<italic>P</italic> &#x0003c; 0.01). Since the number and size of other cardiac cells remained unchanged, this indicated that the number of cardiomyocytes has increased. As a result of &#x003b5;PKC activation, hyperplasia, a phenomenon restricted mainly to perinatal cardiac development, may have occurred.<sup><xref ref-type="bibr" rid="CVP001C36">36</xref></sup> These data suggest that &#x003b5;PKC signalling may be part of a compensatory signalling pathway that is pro-proliferative at least during early post-natal development. This conclusion was further supported by work examining a cross between G&#x003b1;q over-expressing mice, which develop a dilated cardiomyopathy phenotype, and transgenic mice with mild activation of &#x003b5;PKC. The double-transgenic progeny exhibited a reduction in cardiac hypertrophy and an improvement in cardiac function compared with the G&#x003b1;q over-expressing mice.<sup><xref ref-type="bibr" rid="CVP001C37">37</xref></sup> Therefore, &#x003b5;PKC appears to be a positive modulator of compensatory cardiac hypertrophy in this mouse model. Because in this model activation of &#x003b5;PKC and G&#x003b1;q were induced from day 1 after birth, the phenotype may reflect restoration of &#x003b5;PKC activity in the G&#x003b1;q-phenotype.<sup><xref ref-type="bibr" rid="CVP001C37">37</xref></sup></p><p>In hypertensive rats, &#x003b5;PKC levels increase during the compensatory stage of cardiac hypertrophy,<sup><xref ref-type="bibr" rid="CVP001C14">14</xref></sup> but &#x003b5;PKC was detrimental in this response. Further activation of &#x003b5;PKC (by a sustained treatment with the PKC-selective activator, &#x003c8;&#x003b5;RACK) increased cardiac fibrosis and HF, whereas &#x003b5;PKC inhibition (by sustained treatment with the &#x003b5;PKC-selective inhibitor, &#x003b5;V1-2) prolonged survival, reduced hypertrophy, excessive fibrosis, vascular remodelling, and inflammation and corrected cardiac dysfunction.<sup><xref ref-type="bibr" rid="CVP001C15">15</xref>,<xref ref-type="bibr" rid="CVP001C16">16</xref></sup></p><p>Thus studies in mice and rats are not in agreement, suggesting either species differences and/or differences due to the tools that were used (pharmacological vs. genetic manipulation of the animals) as well as the timing of regulation of PKC (i.e. before and/or during the disease course.). A summary of a number of studies using pharmacological and genetic approaches to determine the role of PKC isozymes in hypertrophy and in HF is provided in <italic>Table&#x000a0;<xref ref-type="table" rid="CVP001TB1">1</xref></italic>.</p></sec><sec id="s3c"><label>3.3</label><title>Protein kinase C in human hypertrophy and heart failure</title><p>Although animal studies were inconclusive using genetic manipulations and pharmacologcial PKC modulators (<italic>Table&#x000a0;<xref ref-type="table" rid="CVP001TB1">1</xref></italic>), studies characterizing the level and activity of PKC isozymes in human HF<sup><xref ref-type="bibr" rid="CVP001C3">3</xref>,<xref ref-type="bibr" rid="CVP001C4">4</xref></sup> provide insight into which isozymes should be focused on as therapeutic targets. For instance, &#x003b1;PKC was found to be critical in cardiomyocyte hypertrophy by knock-out and over-expression studies in mice.<sup><xref ref-type="bibr" rid="CVP001C22">22</xref>,<xref ref-type="bibr" rid="CVP001C28">28</xref>,<xref ref-type="bibr" rid="CVP001C29">29</xref></sup> Though activation of &#x003b1;PKC is critical in mouse model of HFs,<sup><xref ref-type="bibr" rid="CVP001C29">29</xref>,<xref ref-type="bibr" rid="CVP001C34">34</xref></sup> activated &#x003b1;PKC levels were found to be low in samples of patients with end-stage HF when compared with normal subjects.<sup><xref ref-type="bibr" rid="CVP001C4">4</xref></sup> Further this study demonstrated that &#x003b1;PKC is activated in the myocardium of patients with aortic stenosis, a condition in which heart functions are not jeopardized. In contrast, both Bowling <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CVP001C3">3</xref></sup> and Simonis <italic>et al</italic>. also<sup><xref ref-type="bibr" rid="CVP001C4">4</xref></sup> found a significant 70 and 150% increase in activation of &#x003b2;PKC, respectively and imunohistochemical staining and mRNA labelling indicated that &#x003b2;PKC is elevated in cardiomyocytes of human HF samples.<sup><xref ref-type="bibr" rid="CVP001C3">3</xref>,<xref ref-type="bibr" rid="CVP001C4">4</xref></sup> LY333531, an inhibitor reported initially to be specific for &#x003b2;PKC,<sup><xref ref-type="bibr" rid="CVP001C38">38</xref></sup> reduced total PKC activity in membrane fractions of failing hearts by 209 pmol min<sup>&#x02212;1</sup>mg<sup>&#x02212;1</sup> suggesting that &#x003b2;PKC constitutes for the majority PKC activity in the failing hearts. Together, these studies indicate that changes in &#x003b2;PKC correlate better with the human HF, suggesting that focusing on this PKC isozyme in considering therapeutic intervention is advisable.</p></sec></sec><sec id="s4"><label>4.</label><title>Cardiac fibrosis</title><p>Fibrosis refers to accumulation of fibroblasts due to increased proliferation, migration, and adhesion of fibroblasts to the site of injury and/or leading to the accumulation of extracellular matrix proteins, such as collagen, by augmented release from fibroblasts or reduced degradation of collagen. Replacement fibrosis, interstitial fibrosis, and perivascular fibrosis are different types of myocardial fibrotic processes, which may occur sequentially or simultaneously. However, an excess of any of these processes interferes with myocardial metabolism, particularly the supply of oxygen and removal of cellular metabolic waste, leading to myocardial malfunctioning, and thus posing detrimental effects to failing hearts. Excess fibrosis can also decrease cardiac elasticity and thus affect cardiac contraction. A variety of pathological stressors, such as ischaemia and hypertension, can trigger cardiac fibrosis. The occurrence of cardiac fibrosis requires a series of coordinated molecular and cellular events that alter the properties of the extracellular matrix (ECM) and cardiac fibroblasts. PKC has been shown to regulate the specific events leading to the deposition of collagen.</p><sec id="s4a"><label>4.1</label><title>Protein kinase C isozymes in cultured cardiac fibroblasts</title><p>&#x003b1;, &#x003b2;I, &#x003b2;II, &#x003b4;, &#x003b5;, and &#x003b6;PKC have been found in both neonatal and adult cardiac fibroblasts and the non-selective PKC activator, PMA, inhibits basal and TGF&#x003b2;-induced thymidine incorporation in these rat fibroblasts.<sup><xref ref-type="bibr" rid="CVP001C39">39</xref></sup> Using isozyme-selective inhibitors, we found that &#x003b4;PKC and &#x003b6;PKC have opposing roles in TGF&#x003b2;-induced fibroblast proliferation, whereas other PKC isozymes have no role in this process.<sup><xref ref-type="bibr" rid="CVP001C39">39</xref></sup> We showed that selective inhibition of &#x003b6;PKC blocked TGF-&#x003b2;1-induced cardiac fibroblast proliferation. In contrast, the &#x003b4;PKC-selective peptide inhibitor, &#x003b4;V1-1, had an opposite effect to that of the &#x003b6;PKC inhibitor; it increased TGF-&#x003b2;1-induced proliferation. Therefore, &#x003b4; and &#x003b6;PKC act downstream of TGF-&#x003b2;1, yielding opposing roles in fibroblast proliferation.</p><p>PKC regulates the levels and activity of matrix metalloproteinases (MMP), a family of zinc-containing proteases, that degrade ECM and facilitate the motility of cardiac fibroblasts.<sup><xref ref-type="bibr" rid="CVP001C40">40</xref>&#x02013;<xref ref-type="bibr" rid="CVP001C44">44</xref></sup> For example, &#x003b1; and &#x003b2;IPKC increase the activity of MMP-9, but not MMP-2, primarily through the JNK-dependent pathway.<sup><xref ref-type="bibr" rid="CVP001C44">44</xref></sup> Other PKCs, such as &#x003b8; and &#x003b6;PKC, increase both MMP-2 and MMP-9 via ERK and NF&#x003ba;B pathways in adult rat cardiac fibroblasts.<sup><xref ref-type="bibr" rid="CVP001C44">44</xref></sup> Ang II binds to angiotensin-type 1 receptor and activates PKC<sup><xref ref-type="bibr" rid="CVP001C45">45</xref></sup> which ultimately leads to fibroblast proliferation.<sup><xref ref-type="bibr" rid="CVP001C46">46</xref>&#x02013;<xref ref-type="bibr" rid="CVP001C48">48</xref></sup> The pro-proliferative effects of other profibrotic stimuli, such as ET-1, were also attenuated by inhibition of PKC with either chelerythrine or staurosporine in neonatal cardiac fibroblasts.<sup><xref ref-type="bibr" rid="CVP001C49">49</xref></sup></p><p>A critical role for &#x003b5;PKC in regulating fibroblast adhesion and migration has also been reported; the effect of Ang II treatment, which induces adhesion and migration in cardiac fibroblasts, was blocked by PKC inhibition, and was abolished in cardiac myofibroblasts obtained from &#x003b5;PKC knockout mice.<sup><xref ref-type="bibr" rid="CVP001C48">48</xref></sup> Additional mechanistic studies demonstrated that &#x003b5;PKC forms a tight complex with &#x003b2;1-integrin to regulate the interaction between the cell and ECM.<sup><xref ref-type="bibr" rid="CVP001C50">50</xref>&#x02013;<xref ref-type="bibr" rid="CVP001C52">52</xref></sup> These findings corroborate a role for &#x003b5;PKC in mediating cardiac fibroblast adhesion and migration.</p></sec><sec id="s4b"><label>4.2</label><title>Protein kinase C in cardiac fibrosis, <italic>in vivo</italic></title><p>A role for PKC in cardiac fibrosis has also been suggested by <italic>in vivo</italic> studies using animal models of HF. Inhibition of classical PKCs, namely, &#x003b1; and &#x003b2;PKC, by ruboxistaurin attenuated pathological fibrosis and improved cardiac function following MI in rats, suggesting a role for classical PKCs in fibrogenesis in the heart.<sup><xref ref-type="bibr" rid="CVP001C12">12</xref></sup> In a recent study, selective &#x003b2;IIPKC inhibition with &#x003b2;IIV5-3 attenuated collagen deposition in the remote region of the myocardium of post-MI HF rats<sup><xref ref-type="bibr" rid="CVP001C53">53</xref></sup> (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP001F2">2</xref></italic>). Hearts from &#x003b5;PKC knock-out mice demonstrated elevated interstitial fibrosis when subjected to pressure overload by transverse aortic constriction.<sup><xref ref-type="bibr" rid="CVP001C54">54</xref></sup> In contrast, sustained inhibition of &#x003b5;PKC by its isozyme-selective peptide inhibitor, &#x003b5;V1-2, suppressed cardiac fibrosis and ameliorated cardiac function, in part by inhibiting MMP-2 activity, in a rat model of hypertension-induced HF.<sup><xref ref-type="bibr" rid="CVP001C15">15</xref></sup> Moreover, &#x003c8;&#x003b5;RACK, an activator of &#x003b5;PKC, augmented the fibrotic process and accelerated mortality in these hypertensive animals. Further, in a rat or mouse cardiac transplantation model, we found that inhibition of &#x003b5;PKC by &#x003b5;V1-2 also blocked parenchymal fibrosis and the increase in TGF-&#x003b2;1 in the grafted heart, corroborating a role for &#x003b5;PKC in cardiac fibrosis <italic>in vivo</italic><sup><xref ref-type="bibr" rid="CVP001C55">55</xref>,<xref ref-type="bibr" rid="CVP001C56">56</xref></sup> (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP001F2">2</xref></italic>). The contradicting findings using &#x003b5;PKC knock-out mice and pharmacological regulation of &#x003b5;PKC in rats suggest that regulation by PKC isozymes may differ according to the aetiology of fibrosis, the species, and/or the extent of activation of compensatory mechanisms (i.e. &#x003b5;PKC null mice have 60% increase in &#x003b4;PKC activity, which may have compensated for &#x003b5;PKC,<sup><xref ref-type="bibr" rid="CVP001C45">45</xref></sup> whereas there is no change in the levels or activity of any PKC isozyme, other than &#x003b5;PKC, when using the &#x003b5;PKC-selective inhibitor<sup><xref ref-type="bibr" rid="CVP001C15">15</xref></sup>). (These and other studies are also listed in <italic>Table&#x000a0;<xref ref-type="table" rid="CVP001TB1">1</xref>.</italic>). Understanding the exquisite control of cardiac fibrosis by PKC could potentially translate to novel effective treatments for cardiac dysfunction and HF.</p></sec></sec><sec id="s5"><label>5.</label><title>Cardiac inflammation</title><p>Irrespective of aetiology, myocardial inflammation is an integral part of HF (i.e. inflammation is found in the myocardium following ischaemia, cardiac infection, autoimmune response, pressure and volume overload, etc.). Though inflammation is often secondary to the trigger for specific cardiac disease, inflammatory cells are a constant source for cytokines, enzymes, and growth factors, which regulate remodelling events such as hypertrophy, fibrosis, and vascularization.</p><sec id="s5a"><label>5.1</label><title>Protein kinase C in cardiac inflammation</title><p>Numerous <italic>in vitro</italic> studies point out the role of PKC isozymes in pro-inflammatory mediator production (transcription and translation) and release.<sup><xref ref-type="bibr" rid="CVP001C57">57</xref>&#x02013;<xref ref-type="bibr" rid="CVP001C62">62</xref></sup> One aspect of cardiac inflammation that is better described is the induction of cell damage by pro-inflammatory cytokines in cardiac diseases or cardiac cells. For example, TNF-&#x003b1; induced apoptosis in coronary vascular endothelial cells seems to be a PKC-mediated event.<sup><xref ref-type="bibr" rid="CVP001C63">63</xref></sup> Sustained inhibition of &#x003b5;PKC by &#x003b5;V1-2 decreased the infiltration of inflammatory cells into the myocardium in the hearts of hypertensive rats with HF.<sup><xref ref-type="bibr" rid="CVP001C16">16</xref></sup> In an MI-induced HF rat model, &#x003b2;IIV5-3, the specific &#x003b2;IIPKC inhibitor, also attenuated infiltration of inflammatory cells<sup><xref ref-type="bibr" rid="CVP001C53">53</xref></sup> (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP001F2">2</xref></italic>). Both of these PKC inhibitors attenuated degranulation of mast cells (MCs), the important inflammatory cells that are involved in HF progression (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP001F2">2</xref></italic>). Likewise, TNF-&#x003b1; production in macrophages is blocked by PKC inhibition with bisindolylmaleimide, a pan PKC inhibitor, or by Go-6976, a classical PKC inhibitor.<sup><xref ref-type="bibr" rid="CVP001C64">64</xref></sup> Further studies on the role of PKC isozymes in the function of important inflammatory cells such as macrophages, T-cells, MCs, and neutrophils in HF progression are needed, because these cells are an integral part of cardiac remodelling and HF.<sup><xref ref-type="bibr" rid="CVP001C65">65</xref>,<xref ref-type="bibr" rid="CVP001C66">66</xref></sup></p></sec></sec><sec id="s6"><label>6.</label><title>Downstream targets of protein kinase C in cardiac remodelling</title><p>As discussed earlier, PKC isozymes regulate fibrosis, inflammation, and cardiac muscle dysfunction and a number of downstream mediators of PKC effects have been identified. Stimulation of primary cultures of adult feline cardiomyocytes with ET-1, PE, PMA, or insulin resulted in phosphorylation and activation of several pro-survival kinases, including mTOR (AKA mammalian Target of Rapamycin; at S2248) and S6K1 (at and T389 S421/T424) via PKC activation. Expression of DN-&#x003b5;PKC abolished ET-1-stimulated mTOR and S6K1 phosphorylation, but not insulin-stimulated S6K1 phosphorylation. ET-1- and insulin-stimulated mTOR and S6K1 phosphorylation in cardiomyocytes was inhibited by expression of DN-&#x003b4;PKC or pre-treatment with rottlerin, a &#x003b4;PKC inhibitor. However, treatment with G&#x000f6;6976, a specific classical PKC (cPKC) inhibitor did not affect mTOR/S6K1 activation. This study demonstrates that &#x003b5; and &#x003b4;PKC activate mTOR and S6 kinase and subsequently lead to cardiomyocyte hypertrophy in cultured feline cardiomyocytes.<sup><xref ref-type="bibr" rid="CVP001C67">67</xref></sup> Another important kinase that has been implicated in hypertrophic signalling is glycogen synthase kinase (GSK). Up-regulation of GSK-3&#x003b1; suppresses cardiac growth and pressure-overload-induced cardiac hypertrophy in mice. Knock-down of GSK-3&#x003b1; increased the phosphorylation of ERK (extracellular signal-regulated kinase), an effect that was inhibited by pharmacological inhibitors of &#x003b5; and &#x003b4;PKC and MEK (mitogen-activated protein kinase kinase), suggesting that GSK-3&#x003b1; inhibits ERK through PKC-MEK-dependent mechanisms and further regulates cardiac hypertrophy.<sup><xref ref-type="bibr" rid="CVP001C68">68</xref></sup> In another study, involvement of PKC in TGF-&#x003b2;1-induced cardiac hypertrophic responses by activating TAK1 (another member of the mitogen-activated kinase kinase kinase family) and ultimately activating transcription factor (ATF). The PKC inhibitors, GO6976 and GF109203X, blocked TGF-&#x003b2;1-induced TAK1 kinase activity and subsequent downstream signalling pathways including ATF-2 phosphorylation, leading to suppression of ATF-2 transcriptional activity.<sup><xref ref-type="bibr" rid="CVP001C69">69</xref></sup> The transcription factor GATA-4 plays a key role in ANF promoter activation in response to pro-hypertrophic Ang II through PKC activation and ultimately resulting in enhanced DNA binding activity.<sup><xref ref-type="bibr" rid="CVP001C70">70</xref></sup> Inhibition of PKC prevents nuclear export of histone deacetylase 5 (HDAC5, a protein regulating myogenesis) in response to hypertrophic agonists. Moreover, a mutation in HDAC5 is refractory to PKC activation. Protein kinase D (PKD), another downstream effector of PKC, directly phosphorylates HDAC5 and stimulates its nuclear export.<sup><xref ref-type="bibr" rid="CVP001C71">71</xref></sup> The stretch-induced increase in cardiac hypertrophy is blocked by inhibition of the small G protein, Rho, or by overexpression of dominant negative &#x003b1; and &#x003b4;PKC, suggesting that &#x003b1; and &#x003b4;PKC are both required for stretch-induced hypertrophy, through Rho GTPase-mediated signalling pathways. Also, phosphorylation of MEK1/ERK1/2 and the MEK kinase, MKK4, and jun kinase, JNK, was inhibited by over-expression of dominant negative &#x003b1; and &#x003b4;PKC.<sup><xref ref-type="bibr" rid="CVP001C72">72</xref></sup></p><p>Myocyte dysfunction in &#x003b1;PKC transgenic mice was caused by alterations in Ca<sup>2+</sup> homeostasis.<sup><xref ref-type="bibr" rid="CVP001C29">29</xref></sup> As discussed, in mice, &#x003b1;PKC depresses myofilament contractility through site-specific phosphorylation of cTnT at the threonine-206 residue in cardiomyocytes.<sup><xref ref-type="bibr" rid="CVP001C30">30</xref></sup> On the other hand, a decreased myofilament responsiveness to Ca2+ was seen in the myocardium of &#x003b2;IIPKC overexpressing transgenic mice as well as a significant increase in the degree of phosphorylation of troponin I. The depressed cardiomyocyte function improved after the sequential superfusion of LY333531, a &#x003b2;PKC inhibitor. This study shows that &#x003b2;IIPKC-mediated phosphorylation of troponin I <italic>in vivo</italic> may decrease myofilament Ca2+ responsiveness, and thus causes cardiomyocyte dysfunction.<sup><xref ref-type="bibr" rid="CVP001C73">73</xref></sup></p><p>Other protein targets of PKC are those involved in ECM regulation. &#x003b5;PKC regulates &#x003b2;1-integrin complex formation with ECM and further participates in the fibrotic events.<sup><xref ref-type="bibr" rid="CVP001C50">50</xref>&#x02013;<xref ref-type="bibr" rid="CVP001C52">52</xref></sup> &#x003b1;, &#x003b2;I, &#x003b5;, &#x003b8;, and &#x003b6;PKC isozymes activate different MMPs to degrade ECM, thereby facilitating the motility of cardiac fibroblasts<sup><xref ref-type="bibr" rid="CVP001C44">44</xref></sup> and inflammatory cells. In inflammatory cells, PKC activation enhances the transcription of cytokine production through phosphorylation of the inhibitor of transcription factor NFkB, IkB.<sup><xref ref-type="bibr" rid="CVP001C74">74</xref></sup> A summary of these and other downstream targets of PKC activation leading to HF is given in <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP001F3">3</xref></italic>.</p><fig id="CVP001F3" position="float"><label>Figure&#x000a0;3</label><caption><p>Schematic protein kinase C isozyme signalling pathways and downstream targets in the heart. The activation of different protein kinase C isozymes contributes to the establishment of heart failure through phosphorylation of isozyme-selective substrates in the failing heart.</p></caption><graphic xlink:href="cvp00103"/></fig></sec><sec id="s7"><label>7.</label><title>Summary and conclusion: should protein kinase C be a target for heart failure treatment?</title><p>Preventing maladaptive cardiac remodelling is a goal of therapy for HF.<sup><xref ref-type="bibr" rid="CVP001C75">75</xref></sup> In this review, we provide evidence that select PKC isozymes play different roles in many aspects of cardiac remodelling in HF (see <italic>Table&#x000a0;<xref ref-type="table" rid="CVP001TB1">1</xref></italic> and <italic>Figures&#x000a0;<xref ref-type="fig" rid="CVP001F2">2</xref></italic> and <italic><xref ref-type="fig" rid="CVP001F3">3</xref></italic>). Because modulators of PKC isozymes are already in clinical trials for a variety of indications,<sup><xref ref-type="bibr" rid="CVP001C76">76</xref>&#x02013;<xref ref-type="bibr" rid="CVP001C84">84</xref></sup> it may now be possible to consider using such PKC isozyme regulators to treat human HF. Although PKC isozymes are present in many tissues, recent clinical trials suggest that systemic delivery of inhibitors and activators of PKC isozymes is well tolerated (see studies with the &#x003b2;PKC small molecule inhibitor,<sup><xref ref-type="bibr" rid="CVP001C77">77</xref>,<xref ref-type="bibr" rid="CVP001C78">78</xref></sup> with the peptide inhibitor of &#x003b4;PKC.<sup><xref ref-type="bibr" rid="CVP001C76">76</xref></sup> Further, new developments in drug delivery suggest that organ-selective delivery may also be possible in the future, for example by delivering slow drug releasing particles to the organ of interest.<sup><xref ref-type="bibr" rid="CVP001C85">85</xref></sup> Therefore, clinical trials with PKC inhibitors to address HF should be considered using either systemic or cardiac-specific drug delivery. Further <italic>in vivo</italic> studies using animal models, including larger animals like dogs, sheep, and pigs, will help guide the identification of the right PKC isozymes that should serve as therapeutic targets for the treatment of pathological cardiac remodelling and HF in humans.</p><p><bold>Conflict of interest:</bold> D.M.-R. is a founder, stock option holder, paid consultant, chair of the scientific advisory board, and member of the board of directors of KAI Pharmaceuticals, a company whose goal is to bring peptide regulators of PKC to the clinic. However, none of the research proposed here and none of the detail of the work done in my laboratory at Stanford is disclosed to the company before it is disclosed publicly elsewhere. D.M.-R. has provided reports on her relationship with KAI to Stanford University (last report was provided in April 2008). S.S.P., L.S., and J.C.B.F. have no conflict of interest to disclose.</p></sec><sec id="s8"><title>Funding</title><p>This work was supported by The <funding-source>National Institutes of Health</funding-source> grant <award-id>HL76675</award-id> to D.M.-R.</p></sec></body><back><ref-list><title>References</title><ref id="CVP001C1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohout</surname><given-names>TA</given-names></name><name><surname>Rogers</surname><given-names>TB</given-names></name></person-group><article-title>Use of a PCR-based method to characterize protein kinase C isoform expression in cardiac cells</article-title><source>Am J Physiol</source><year>1993</year><volume>264</volume><fpage>C1350</fpage><lpage>C1359</lpage><pub-id pub-id-type="pmid">7684564</pub-id></element-citation></ref><ref id="CVP001C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdbrugger</surname><given-names>W</given-names></name><name><surname>Keffel</surname><given-names>J</given-names></name><name><surname>Knocks</surname><given-names>M</given-names></name><name><surname>Otto</surname><given-names>T</given-names></name><name><surname>Philipp</surname><given-names>T</given-names></name><name><surname>Michel</surname><given-names>MC</given-names></name></person-group><article-title>Protein kinase C isoenzymes in rat and human cardiovascular tissues</article-title><source>Br J Pharmacol</source><year>1997</year><volume>120</volume><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">9117107</pub-id></element-citation></ref><ref id="CVP001C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowling</surname><given-names>N</given-names></name><name><surname>Walsh</surname><given-names>RA</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Estridge</surname><given-names>T</given-names></name><name><surname>Sandusky</surname><given-names>GE</given-names></name><name><surname>Fouts</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">9918525</pub-id></element-citation></ref><ref id="CVP001C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonis</surname><given-names>G</given-names></name><name><surname>Briem</surname><given-names>SK</given-names></name><name><surname>Schoen</surname><given-names>SP</given-names></name><name><surname>Bock</surname><given-names>M</given-names></name><name><surname>Marquetant</surname><given-names>R</given-names></name><name><surname>Strasser</surname><given-names>RH</given-names></name></person-group><article-title>Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy</article-title><source>Mol Cell Biochem</source><year>2007</year><volume>305</volume><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">17594058</pub-id></element-citation></ref><ref id="CVP001C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>HG</given-names></name><name><surname>Barnett</surname><given-names>JV</given-names></name><name><surname>Chang</surname><given-names>P</given-names></name><name><surname>Reddy</surname><given-names>S</given-names></name><name><surname>Drinkwater</surname><given-names>DC</given-names></name><name><surname>Pierson</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Molecular heterogeneity of protein kinase C expression in human ventricle</article-title><source>Cardiovasc Res</source><year>2000</year><volume>48</volume><fpage>285</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">11054475</pub-id></element-citation></ref><ref id="CVP001C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Disatnik</surname><given-names>MH</given-names></name><name><surname>Buraggi</surname><given-names>G</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Localization of protein kinase C isozymes in cardiac myocytes</article-title><source>Exp Cell Res</source><year>1994</year><volume>210</volume><fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">8299726</pub-id></element-citation></ref><ref id="CVP001C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>KL</given-names></name><name><surname>Paquet</surname><given-names>L</given-names></name><name><surname>Allen</surname><given-names>BG</given-names></name><name><surname>Rindt</surname><given-names>H</given-names></name></person-group><article-title>Protein kinase C isoform expression and activity in the mouse heart</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>281</volume><fpage>H2062</fpage><lpage>H2071</lpage><pub-id pub-id-type="pmid">11668067</pub-id></element-citation></ref><ref id="CVP001C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouet-Benzineb</surname><given-names>P</given-names></name><name><surname>Mohammadi</surname><given-names>K</given-names></name><name><surname>Perennec</surname><given-names>J</given-names></name><name><surname>Poyard</surname><given-names>M</given-names></name><name><surname>Bouanani Nel</surname><given-names>H</given-names></name><name><surname>Crozatier</surname><given-names>B</given-names></name></person-group><article-title>Protein kinase C isoform expression in normal and failing rabbit hearts</article-title><source>Circ Res</source><year>1996</year><volume>79</volume><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">8755991</pub-id></element-citation></ref><ref id="CVP001C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchill</surname><given-names>E</given-names></name><name><surname>Budas</surname><given-names>G</given-names></name><name><surname>Vallentin</surname><given-names>A</given-names></name><name><surname>Koyanagi</surname><given-names>T</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>PKC isozymes in chronic cardiac disease: possible therapeutic targets?</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2008</year><volume>48</volume><fpage>569</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">17919087</pub-id></element-citation></ref><ref id="CVP001C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budas</surname><given-names>GR</given-names></name><name><surname>Churchill</surname><given-names>EN</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury</article-title><source>Pharmacol Res</source><year>2007</year><volume>55</volume><fpage>523</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">17576073</pub-id></element-citation></ref><ref id="CVP001C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakasaki</surname><given-names>H</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Schoen</surname><given-names>FJ</given-names></name><name><surname>Jirousek</surname><given-names>MR</given-names></name><name><surname>Ways</surname><given-names>DK</given-names></name><name><surname>Hoit</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>9320</fpage><lpage>9325</lpage><pub-id pub-id-type="pmid">9256480</pub-id></element-citation></ref><ref id="CVP001C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>AJ</given-names></name><name><surname>Kelly</surname><given-names>DJ</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cox</surname><given-names>AJ</given-names></name><name><surname>Gow</surname><given-names>RM</given-names></name><name><surname>Way</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction</article-title><source>J Mol Cell Cardiol</source><year>2005</year><volume>39</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">15878171</pub-id></element-citation></ref><ref id="CVP001C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabri</surname><given-names>A</given-names></name><name><surname>Steinberg</surname><given-names>SF</given-names></name></person-group><article-title>Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure</article-title><source>Mol Cell Biochem</source><year>2003</year><volume>251</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">14575310</pub-id></element-citation></ref><ref id="CVP001C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Iwanaga</surname><given-names>Y</given-names></name><name><surname>Sarai</surname><given-names>N</given-names></name><name><surname>Onozawa</surname><given-names>Y</given-names></name><name><surname>Takenaka</surname><given-names>H</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><etal/></person-group><article-title>Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta</article-title><source>J Mol Cell Cardiol</source><year>2002</year><volume>34</volume><fpage>1377</fpage><lpage>1385</lpage><pub-id pub-id-type="pmid">12392998</pub-id></element-citation></ref><ref id="CVP001C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Koyanagi</surname><given-names>T</given-names></name><name><surname>Berry</surname><given-names>NC</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure</article-title><source>Hypertension</source><year>2008</year><volume>51</volume><fpage>1565</fpage><lpage>1569</lpage><pub-id pub-id-type="pmid">18413490</pub-id></element-citation></ref><ref id="CVP001C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palaniyandi</surname><given-names>SS</given-names></name><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Mast cells and varepsilonPKC: A role in cardiac remodeling in hypertension-induced heart failure</article-title><source>J Mol Cell Cardiol</source><year>2008</year><volume>45</volume><fpage>779</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">18804478</pub-id></element-citation></ref><ref id="CVP001C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Begley</surname><given-names>R</given-names></name><name><surname>Ikeno</surname><given-names>F</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Cardioprotection by epsilon-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase C-activating peptide</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">15611364</pub-id></element-citation></ref><ref id="CVP001C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>SA</given-names></name><name><surname>Baker</surname><given-names>DW</given-names></name><name><surname>Chin</surname><given-names>MH</given-names></name><name><surname>Cinquegrani</surname><given-names>MP</given-names></name><name><surname>Feldman</surname><given-names>AM</given-names></name><name><surname>Francis</surname><given-names>GS</given-names></name><etal/></person-group><article-title>ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America</article-title><source>Circulation</source><year>2001</year><volume>104</volume><fpage>2996</fpage><lpage>3007</lpage><pub-id pub-id-type="pmid">11739319</pub-id></element-citation></ref><ref id="CVP001C19"><label>19</label><element-citation publication-type="journal"><collab>AHA heart disease and stroke statistics; 2003 update</collab></element-citation></ref><ref id="CVP001C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gheorghiade</surname><given-names>M</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name></person-group><article-title>Chronic heart failure in the United States: a manifestation of coronary artery disease</article-title><source>Circulation</source><year>1998</year><volume>97</volume><fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">9462531</pub-id></element-citation></ref><ref id="CVP001C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>JJ</given-names></name><name><surname>Chien</surname><given-names>KR</given-names></name></person-group><article-title>Signaling pathways for cardiac hypertrophy and failure</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>1276</fpage><lpage>1283</lpage><pub-id pub-id-type="pmid">10528039</pub-id></element-citation></ref><ref id="CVP001C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vijayan</surname><given-names>K</given-names></name><name><surname>Szotek</surname><given-names>EL</given-names></name><name><surname>Martin</surname><given-names>JL</given-names></name><name><surname>Samarel</surname><given-names>AM</given-names></name></person-group><article-title>Protein kinase C-alpha-induced hypertrophy of neonatal rat ventricular myocytes</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2004</year><volume>287</volume><fpage>H2777</fpage><lpage>H2789</lpage><pub-id pub-id-type="pmid">15271671</pub-id></element-citation></ref><ref id="CVP001C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerkela</surname><given-names>R</given-names></name><name><surname>Ilves</surname><given-names>M</given-names></name><name><surname>Pikkarainen</surname><given-names>S</given-names></name><name><surname>Tokola</surname><given-names>H</given-names></name><name><surname>Ronkainen</surname><given-names>J</given-names></name><name><surname>Vuolteenaho</surname><given-names>O</given-names></name><etal/></person-group><article-title>Identification of PKCalpha isoform-specific effects in cardiac myocytes using antisense phosphorothioate oligonucleotides</article-title><source>Mol Pharmacol</source><year>2002</year><volume>62</volume><fpage>1482</fpage><lpage>1491</lpage><pub-id pub-id-type="pmid">12435817</pub-id></element-citation></ref><ref id="CVP001C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braz</surname><given-names>JC</given-names></name><name><surname>Bueno</surname><given-names>OF</given-names></name><name><surname>De Windt</surname><given-names>LJ</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name></person-group><article-title>PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2)</article-title><source>J Cell Biol</source><year>2002</year><volume>156</volume><fpage>905</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">11864993</pub-id></element-citation></ref><ref id="CVP001C25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stebbins</surname><given-names>EG</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>29644</fpage><lpage>29650</lpage><pub-id pub-id-type="pmid">11387319</pub-id></element-citation></ref><ref id="CVP001C26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallentin</surname><given-names>A</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>RBCK1, a protein kinase CbetaI (PKCbetaI)-interacting protein, regulates PKCbeta-dependent function</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>1650</fpage><lpage>1657</lpage><pub-id pub-id-type="pmid">17121852</pub-id></element-citation></ref><ref id="CVP001C27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sil</surname><given-names>P</given-names></name><name><surname>Kandaswamy</surname><given-names>V</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name></person-group><article-title>Increased protein kinase C activity in myotrophin-induced myocyte growth</article-title><source>Circ Res</source><year>1998</year><volume>82</volume><fpage>1173</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">9633917</pub-id></element-citation></ref><ref id="CVP001C28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belin</surname><given-names>RJ</given-names></name><name><surname>Sumandea</surname><given-names>MP</given-names></name><name><surname>Allen</surname><given-names>EJ</given-names></name><name><surname>Schoenfelt</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Augmented protein kinase C-alpha-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure</article-title><source>Circ Res</source><year>2007</year><volume>101</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">17556659</pub-id></element-citation></ref><ref id="CVP001C29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braz</surname><given-names>JC</given-names></name><name><surname>Gregory</surname><given-names>K</given-names></name><name><surname>Pathak</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Sahin</surname><given-names>B</given-names></name><name><surname>Klevitsky</surname><given-names>R</given-names></name><etal/></person-group><article-title>PKC-alpha regulates cardiac contractility and propensity toward heart failure</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">14966518</pub-id></element-citation></ref><ref id="CVP001C30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumandea</surname><given-names>MP</given-names></name><name><surname>Pyle</surname><given-names>WG</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>de Tombe</surname><given-names>PP</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name></person-group><article-title>Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>35135</fpage><lpage>35144</lpage><pub-id pub-id-type="pmid">12832403</pub-id></element-citation></ref><ref id="CVP001C31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>JC</given-names></name><name><surname>TK</surname></name><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Fajardo</surname><given-names>G</given-names></name><name><surname>Churchill</surname><given-names>EN</given-names></name><name><surname>Budas</surname><given-names>G</given-names></name><etal/></person-group><article-title>Pharmacological inhibition of &#x003b2;IIPKC is cardioprotective in late-stage hypertrophy and end-stage heart failure</article-title><comment>(Unpublished observation)</comment></element-citation></ref><ref id="CVP001C32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowman</surname><given-names>JC</given-names></name><name><surname>Steinberg</surname><given-names>SF</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Geenen</surname><given-names>DL</given-names></name><name><surname>Fishman</surname><given-names>GI</given-names></name><name><surname>Buttrick</surname><given-names>PM</given-names></name></person-group><article-title>Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates</article-title><source>The Journal of clinical investigation</source><year>1997</year><volume>100</volume><fpage>2189</fpage><lpage>2195</lpage><pub-id pub-id-type="pmid">9410895</pub-id></element-citation></ref><ref id="CVP001C33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murriel</surname><given-names>CL</given-names></name><name><surname>Churchill</surname><given-names>E</given-names></name><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Szweda</surname><given-names>LI</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Protein kinase Cdelta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>47985</fpage><lpage>47991</lpage><pub-id pub-id-type="pmid">15339931</pub-id></element-citation></ref><ref id="CVP001C34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hambleton</surname><given-names>M</given-names></name><name><surname>Hahn</surname><given-names>H</given-names></name><name><surname>Pleger</surname><given-names>ST</given-names></name><name><surname>Kuhn</surname><given-names>MC</given-names></name><name><surname>Klevitsky</surname><given-names>R</given-names></name><name><surname>Carr</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>574</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">16880328</pub-id></element-citation></ref><ref id="CVP001C35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>BB</given-names></name><name><surname>Geenen</surname><given-names>DL</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Buttrick</surname><given-names>PM</given-names></name></person-group><article-title>PKC-beta is not necessary for cardiac hypertrophy</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>280</volume><fpage>H2264</fpage><lpage>H2270</lpage><pub-id pub-id-type="pmid">11299230</pub-id></element-citation></ref><ref id="CVP001C36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Hahn</surname><given-names>H</given-names></name><name><surname>Osinska</surname><given-names>H</given-names></name><name><surname>Liron</surname><given-names>T</given-names></name><name><surname>Lorenz</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation</article-title><source>Circ Res</source><year>2000</year><volume>86</volume><fpage>1173</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">10850970</pub-id></element-citation></ref><ref id="CVP001C37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Toyokawa</surname><given-names>T</given-names></name><name><surname>Hahn</surname><given-names>H</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names><suffix>2nd</suffix></name></person-group><article-title>Epsilon protein kinase C in pathological myocardial hypertrophy. Analysis by combined transgenic expression of translocation modifiers and Galphaq</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>29927</fpage><lpage>29930</lpage><pub-id pub-id-type="pmid">10899155</pub-id></element-citation></ref><ref id="CVP001C38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Jirousek</surname><given-names>MR</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Takagi</surname><given-names>C</given-names></name><name><surname>Xia</surname><given-names>P</given-names></name><name><surname>Clermont</surname><given-names>A</given-names></name><etal/></person-group><article-title>Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor</article-title><source>Science</source><year>1996</year><volume>272</volume><fpage>728</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">8614835</pub-id></element-citation></ref><ref id="CVP001C39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>MU</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Opposing effects of delta- and zeta-protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors</article-title><source>Journal of molecular and cellular cardiology</source><year>2003</year><volume>35</volume><fpage>895</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">12878476</pub-id></element-citation></ref><ref id="CVP001C40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name></person-group><article-title>Secretions of MMP-9 by soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) mediated by protein kinase C (PKC)delta and phospholipase D (PLD) in murine macrophage</article-title><source>J Cell Biochem</source><year>2004</year><volume>92</volume><fpage>481</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">15156560</pub-id></element-citation></ref><ref id="CVP001C41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>MJ</given-names></name><name><surname>Park</surname><given-names>IC</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Woo</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Hong</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Protein kinase C-alpha activation by phorbol ester induces secretion of gelatinase B/MMP-9 through ERK 1/2 pathway in capillary endothelial cells</article-title><source>Int J Oncol</source><year>2003</year><volume>22</volume><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">12469196</pub-id></element-citation></ref><ref id="CVP001C42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuben</surname><given-names>PM</given-names></name><name><surname>Cheung</surname><given-names>HS</given-names></name></person-group><article-title>Regulation of matrix metalloproteinase (MMP) gene expression by protein kinases</article-title><source>Front Biosci</source><year>2006</year><volume>11</volume><fpage>1199</fpage><lpage>1215</lpage><pub-id pub-id-type="pmid">16368506</pub-id></element-citation></ref><ref id="CVP001C43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>B</given-names></name><name><surname>Laouar</surname><given-names>A</given-names></name><name><surname>Huberman</surname><given-names>E</given-names></name></person-group><article-title>Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/gelatinase (MMP-9) gene expression during macrophage differentiation. The signaling role of protein kinase C-beta</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>11576</fpage><lpage>11582</lpage><pub-id pub-id-type="pmid">9565574</pub-id></element-citation></ref><ref id="CVP001C44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>K</given-names></name></person-group><article-title>Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>39513</fpage><lpage>39519</lpage><pub-id pub-id-type="pmid">15269222</pub-id></element-citation></ref><ref id="CVP001C45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>MO</given-names></name><name><surname>Long</surname><given-names>CS</given-names></name><name><surname>Kalinyak</surname><given-names>JE</given-names></name><name><surname>Li</surname><given-names>HT</given-names></name><name><surname>Karliner</surname><given-names>JS</given-names></name></person-group><article-title>Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts</article-title><source>Cardiovasc Res</source><year>1998</year><volume>40</volume><fpage>352</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">9893729</pub-id></element-citation></ref><ref id="CVP001C46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booz</surname><given-names>GW</given-names></name><name><surname>Dostal</surname><given-names>DE</given-names></name><name><surname>Singer</surname><given-names>HA</given-names></name><name><surname>Baker</surname><given-names>KM</given-names></name></person-group><article-title>Involvement of protein kianse C and Ca2+ in angiotensin II-induced mitogenesis of cardiac fibroblasts</article-title><source>Am J Physiol</source><year>1994</year><volume>267</volume><fpage>C1308</fpage><lpage>C1318</lpage><pub-id pub-id-type="pmid">7977694</pub-id></element-citation></ref><ref id="CVP001C47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>Pantev</surname><given-names>E</given-names></name><name><surname>Moller</surname><given-names>S</given-names></name><name><surname>Erlinge</surname><given-names>D</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Angiotensin II type 1 receptors stimulate protein synthesis in human cardiac fibroblasts via a Ca2+-sensitive PKC-dependent tyrosine kinase pathway</article-title><source>Acta Physiol Scand</source><year>2000</year><volume>168</volume><fpage>301</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">10712568</pub-id></element-citation></ref><ref id="CVP001C48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stawowy</surname><given-names>P</given-names></name><name><surname>Margeta</surname><given-names>C</given-names></name><name><surname>Blaschke</surname><given-names>F</given-names></name><name><surname>Lindschau</surname><given-names>C</given-names></name><name><surname>Spencer-Hansch</surname><given-names>C</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><etal/></person-group><article-title>Protein kinase C epsilon mediates angiotensin II-induced activation of beta1-integrins in cardiac fibroblasts</article-title><source>Cardiovasc Res</source><year>2005</year><volume>67</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">15949469</pub-id></element-citation></ref><ref id="CVP001C49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piacentini</surname><given-names>L</given-names></name><name><surname>Gray</surname><given-names>M</given-names></name><name><surname>Honbo</surname><given-names>NY</given-names></name><name><surname>Chentoufi</surname><given-names>J</given-names></name><name><surname>Bergman</surname><given-names>M</given-names></name><name><surname>Karliner</surname><given-names>JS</given-names></name></person-group><article-title>Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C</article-title><source>J Mol Cell Cardiol</source><year>2000</year><volume>32</volume><fpage>565</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">10756114</pub-id></element-citation></ref><ref id="CVP001C50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besson</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>TL</given-names></name><name><surname>Yong</surname><given-names>VW</given-names></name></person-group><article-title>The anchoring protein RACK1 links protein kinase Cepsilon to integrin beta chains. Requirements for adhesion and motility</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>22073</fpage><lpage>22084</lpage><pub-id pub-id-type="pmid">11934885</pub-id></element-citation></ref><ref id="CVP001C51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidkamp</surname><given-names>MC</given-names></name><name><surname>Bayer</surname><given-names>AL</given-names></name><name><surname>Scully</surname><given-names>BT</given-names></name><name><surname>Eble</surname><given-names>DM</given-names></name><name><surname>Samarel</surname><given-names>AM</given-names></name></person-group><article-title>Activation of focal adhesion kinase by protein kinase C epsilon in neonatal rat ventricular myocytes</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2003</year><volume>285</volume><fpage>H1684</fpage><lpage>H1696</lpage><pub-id pub-id-type="pmid">12829427</pub-id></element-citation></ref><ref id="CVP001C52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivaska</surname><given-names>J</given-names></name><name><surname>Whelan</surname><given-names>RD</given-names></name><name><surname>Watson</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>PJ</given-names></name></person-group><article-title>PKC epsilon controls the traffic of beta1 integrins in motile cells</article-title><source>EMBO J</source><year>2002</year><volume>21</volume><fpage>3608</fpage><lpage>3619</lpage><pub-id pub-id-type="pmid">12110574</pub-id></element-citation></ref><ref id="CVP001C53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palaniyandi</surname><given-names>SS</given-names></name><name><surname>Ferreira</surname><given-names>JCB</given-names></name><name><surname>Brum</surname><given-names>P</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>&#x003b2;IIPKC inhibition reduces post-myocardial infarction-induced end-stage heart failure in rats</article-title><year>2008</year><comment>(Unpublished observation)</comment></element-citation></ref><ref id="CVP001C54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>G</given-names></name><name><surname>Schaefer</surname><given-names>A</given-names></name><name><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name><name><surname>Oppermann</surname><given-names>D</given-names></name><name><surname>Shukla</surname><given-names>P</given-names></name><name><surname>Quint</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon</article-title><source>Circ Res</source><year>2005</year><volume>96</volume><fpage>748</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">15761199</pub-id></element-citation></ref><ref id="CVP001C55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Gunawan</surname><given-names>F</given-names></name><name><surname>Terry</surname><given-names>RD</given-names></name><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Caffarelli</surname><given-names>AD</given-names></name><name><surname>Hoyt</surname><given-names>G</given-names></name><etal/></person-group><article-title>Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators</article-title><source>J Thorac Cardiovasc Surg</source><year>2005</year><volume>129</volume><fpage>1160</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">15867794</pub-id></element-citation></ref><ref id="CVP001C56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyanagi</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>K</given-names></name><name><surname>Ootani</surname><given-names>A</given-names></name><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Robbins</surname><given-names>RC</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Pharmacological inhibition of epsilon PKC suppresses chronic inflammation in murine cardiac transplantation model</article-title><source>J Mol Cell Cardiol</source><year>2007</year><volume>43</volume><fpage>517</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">17655859</pub-id></element-citation></ref><ref id="CVP001C57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname><given-names>L</given-names></name><name><surname>Sylvia</surname><given-names>VL</given-names></name><name><surname>Halabi</surname><given-names>A</given-names></name><name><surname>Soskolne</surname><given-names>WA</given-names></name><name><surname>Van Dyke</surname><given-names>TE</given-names></name><name><surname>Dean</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Bacterial lipopolysaccharide induces early and late activation of protein kinase C in inflammatory macrophages by selective activation of PKC-epsilon</article-title><source>Biochem Biophys Res Commun</source><year>1997</year><volume>240</volume><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">9398616</pub-id></element-citation></ref><ref id="CVP001C58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>A</given-names></name><name><surname>Doherty</surname><given-names>K</given-names></name><name><surname>Plevin</surname><given-names>R</given-names></name></person-group><article-title>Differential regulation by protein kinase C isoforms of nitric oxide synthase induction in RAW 264.7 macrophages and rat aortic smooth muscle cells</article-title><source>Br J Pharmacol</source><year>1997</year><volume>120</volume><fpage>940</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">9138702</pub-id></element-citation></ref><ref id="CVP001C59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>MA</given-names></name><name><surname>LeMieur</surname><given-names>T</given-names></name><name><surname>Clair</surname><given-names>L</given-names></name><name><surname>Bellingham</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>JL</given-names></name></person-group><article-title>Protein kinase C regulates macrophage tumor necrosis factor secretion: direct protein kinase C activation restores tumor necrosis factor production in endotoxin tolerance</article-title><source>Surgery</source><year>1997</year><volume>122</volume><fpage>204</fpage><lpage>211</lpage><comment>discussion 211&#x02013;202</comment><pub-id pub-id-type="pmid">9288124</pub-id></element-citation></ref><ref id="CVP001C60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Venugopal</surname><given-names>SK</given-names></name><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name></person-group><article-title>Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">15616014</pub-id></element-citation></ref><ref id="CVP001C61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nechushtan</surname><given-names>H</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Kay</surname><given-names>G</given-names></name><name><surname>Razin</surname><given-names>E</given-names></name></person-group><article-title>Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase Cbeta</article-title><source>Blood</source><year>2000</year><volume>95</volume><fpage>1752</fpage><lpage>1757</lpage><pub-id pub-id-type="pmid">10688834</pub-id></element-citation></ref><ref id="CVP001C62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikodemova</surname><given-names>M</given-names></name><name><surname>Watters</surname><given-names>JJ</given-names></name><name><surname>Jackson</surname><given-names>SJ</given-names></name><name><surname>Yang</surname><given-names>SK</given-names></name><name><surname>Duncan</surname><given-names>ID</given-names></name></person-group><article-title>Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>15208</fpage><lpage>15216</lpage><pub-id pub-id-type="pmid">17395590</pub-id></element-citation></ref><ref id="CVP001C63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Mehta</surname><given-names>JL</given-names></name></person-group><article-title>Tumor necrosis factor-alpha enhances hypoxia-reoxygenation-mediated apoptosis in cultured human coronary artery endothelial cells: critical role of protein kinase C</article-title><source>Cardiovasc Res</source><year>1999</year><volume>42</volume><fpage>805</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">10533621</pub-id></element-citation></ref><ref id="CVP001C64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meldrum</surname><given-names>DR</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Sheridan</surname><given-names>BC</given-names></name><name><surname>McIntyre</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Harken</surname><given-names>AH</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name></person-group><article-title>Tissue-specific protein kinase C isoforms differentially mediate macrophage TNFalpha and IL-1beta production</article-title><source>Shock</source><year>1998</year><volume>9</volume><fpage>256</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">9565253</pub-id></element-citation></ref><ref id="CVP001C65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrovic</surname><given-names>D</given-names></name></person-group><article-title>Cytopathological basis of heart failure&#x02013;cardiomyocyte apoptosis, interstitial fibrosis and inflammatory cell response</article-title><source>Folia Biol (Praha)</source><year>2004</year><volume>5</volume><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15222127</pub-id></element-citation></ref><ref id="CVP001C66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>DL</given-names></name></person-group><article-title>Inflammatory mediators and the failing heart: past, present, and the foreseeable future</article-title><source>Circ Res</source><year>2002</year><volume>91</volume><fpage>988</fpage><lpage>998</lpage><pub-id pub-id-type="pmid">12456484</pub-id></element-citation></ref><ref id="CVP001C67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moschella</surname><given-names>PC</given-names></name><name><surname>Rao</surname><given-names>VU</given-names></name><name><surname>McDermott</surname><given-names>PJ</given-names></name><name><surname>Kuppuswamy</surname><given-names>D</given-names></name></person-group><article-title>Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCepsilon and PKCdelta, in adult cardiac muscle cells</article-title><source>J Mol Cell Cardiol</source><year>2007</year><volume>43</volume><fpage>754</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">17976640</pub-id></element-citation></ref><ref id="CVP001C68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>P</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Holle</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Yatani</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>T</given-names></name><etal/></person-group><article-title>Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>33181</fpage><lpage>33191</lpage><pub-id pub-id-type="pmid">17855351</pub-id></element-citation></ref><ref id="CVP001C69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Hwang</surname><given-names>HY</given-names></name><name><surname>Park</surname><given-names>EJ</given-names></name><name><surname>Nam</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation</article-title><source>J Mol Cell Cardiol</source><year>2005</year><volume>39</volume><fpage>627</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">16125722</pub-id></element-citation></ref><ref id="CVP001C70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Paradis</surname><given-names>P</given-names></name><name><surname>Aries</surname><given-names>A</given-names></name><name><surname>Komati</surname><given-names>H</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4</article-title><source>Mol Cell Biol</source><year>2005</year><volume>25</volume><fpage>9829</fpage><lpage>9844</lpage><pub-id pub-id-type="pmid">16260600</pub-id></element-citation></ref><ref id="CVP001C71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vega</surname><given-names>RB</given-names></name><name><surname>Harrison</surname><given-names>BC</given-names></name><name><surname>Meadows</surname><given-names>E</given-names></name><name><surname>Roberts</surname><given-names>CR</given-names></name><name><surname>Papst</surname><given-names>PJ</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name><etal/></person-group><article-title>Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><fpage>8374</fpage><lpage>8385</lpage><pub-id pub-id-type="pmid">15367659</pub-id></element-citation></ref><ref id="CVP001C72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>US</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Oka</surname><given-names>Y</given-names></name><name><surname>Palm-Leis</surname><given-names>A</given-names></name><name><surname>Herbelin</surname><given-names>BS</given-names></name><etal/></person-group><article-title>PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and mitogen-activated protein kinases in cardiomyocytes</article-title><source>J Cell Physiol</source><year>2005</year><volume>202</volume><fpage>536</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">15316932</pub-id></element-citation></ref><ref id="CVP001C73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeishi</surname><given-names>Y</given-names></name><name><surname>Chu</surname><given-names>G</given-names></name><name><surname>Kirkpatrick</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wakasaki</surname><given-names>H</given-names></name><name><surname>Kranias</surname><given-names>EG</given-names></name><etal/></person-group><article-title>In vivo phosphorylation of cardiac troponin I by protein kinase Cbeta2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts</article-title><source>J Clin Invest</source><year>1998</year><volume>102</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">9649559</pub-id></element-citation></ref><ref id="CVP001C74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiner</surname><given-names>G</given-names></name><name><surname>Oliver</surname><given-names>M</given-names></name><name><surname>Skamene</surname><given-names>E</given-names></name><name><surname>Radzioch</surname><given-names>D</given-names></name></person-group><article-title>Induction of tumor necrosis factor alpha gene expression by lipoprotein lipase requires protein kinase C activation</article-title><source>J Lipid Res</source><year>1994</year><volume>35</volume><fpage>1413</fpage><lpage>1421</lpage><pub-id pub-id-type="pmid">7527452</pub-id></element-citation></ref><ref id="CVP001C75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>JN</given-names></name><name><surname>Ferrari</surname><given-names>R</given-names></name><name><surname>Sharpe</surname><given-names>N</given-names></name></person-group><article-title>Cardiac remodeling&#x02013;concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling</article-title><source>J Am Coll Cardiol</source><year>2000</year><volume>35</volume><fpage>569</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">10716457</pub-id></element-citation></ref><ref id="CVP001C76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>E</given-names></name><name><surname>Bode</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><name><surname>Granger</surname><given-names>C</given-names></name><name><surname>Green</surname><given-names>C</given-names></name><etal/></person-group><article-title>Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction</article-title><source>Circulation</source><year>2008</year><volume>117</volume><fpage>886</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">18250271</pub-id></element-citation></ref><ref id="CVP001C77"><label>77</label><element-citation publication-type="journal"><collab>The PKC-DRS Study Group</collab><article-title>The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>2188</fpage><lpage>2197</lpage><pub-id pub-id-type="pmid">15983221</pub-id></element-citation></ref><ref id="CVP001C78"><label>78</label><element-citation publication-type="journal"><collab>The PKC-DRS Study Group</collab><article-title>Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial</article-title><source>Arch Ophthalmol</source><year>2007</year><volume>125</volume><fpage>318</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">17353401</pub-id></element-citation></ref><ref id="CVP001C79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Advani</surname><given-names>R</given-names></name><name><surname>Peethambaram</surname><given-names>P</given-names></name><name><surname>Lum</surname><given-names>BL</given-names></name><name><surname>Fisher</surname><given-names>GA</given-names></name><name><surname>Hartmann</surname><given-names>L</given-names></name><name><surname>Long</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma</article-title><source>Cancer</source><year>2004</year><volume>100</volume><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">14716767</pub-id></element-citation></ref><ref id="CVP001C80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Faust</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>BB</given-names></name><name><surname>Ho</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>JC</given-names></name><etal/></person-group><article-title>A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma</article-title><source>Invest New Drugs</source><year>2006</year><volume>24</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">16683077</pub-id></element-citation></ref><ref id="CVP001C81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casellini</surname><given-names>CM</given-names></name><name><surname>Barlow</surname><given-names>PM</given-names></name><name><surname>Rice</surname><given-names>AL</given-names></name><name><surname>Casey</surname><given-names>M</given-names></name><name><surname>Simmons</surname><given-names>K</given-names></name><name><surname>Pittenger</surname><given-names>G</given-names></name><etal/></person-group><article-title>A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>896</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">17392551</pub-id></element-citation></ref><ref id="CVP001C82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>SA</given-names></name><name><surname>Alavi</surname><given-names>JB</given-names></name><name><surname>Supko</surname><given-names>JG</given-names></name><name><surname>Carson</surname><given-names>KA</given-names></name><name><surname>Priet</surname><given-names>R</given-names></name><name><surname>Dorr</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas</article-title><source>Neuro Oncol</source><year>2005</year><volume>7</volume><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">15701280</pub-id></element-citation></ref><ref id="CVP001C83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Oh</surname><given-names>Y</given-names></name><name><surname>Wagle</surname><given-names>A</given-names></name><name><surname>Lahn</surname><given-names>M</given-names></name></person-group><article-title>Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>s4641</fpage><lpage>s4646</lpage><pub-id pub-id-type="pmid">17671157</pub-id></element-citation></ref><ref id="CVP001C84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritch</surname><given-names>P</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Bitran</surname><given-names>JD</given-names></name><name><surname>Edelman</surname><given-names>MJ</given-names></name><name><surname>Makalinao</surname><given-names>A</given-names></name><name><surname>Irwin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer</article-title><source>Lung Cancer</source><year>2006</year><volume>52</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">16507327</pub-id></element-citation></ref><ref id="CVP001C85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>CR</given-names></name><name><surname>Bekeredjian</surname><given-names>R</given-names></name></person-group><article-title>Ultrasonic gene and drug delivery to the cardiovascular system</article-title><source>Adv Drug Deliv Rev</source><year>2008</year><volume>60</volume><fpage>1177</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">18474407</pub-id></element-citation></ref><ref id="CVP001C86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoguchi</surname><given-names>T</given-names></name><name><surname>Battan</surname><given-names>R</given-names></name><name><surname>Handler</surname><given-names>E</given-names></name><name><surname>Sportsman</surname><given-names>JR</given-names></name><name><surname>Heath</surname><given-names>W</given-names></name><name><surname>King</surname><given-names>GL</given-names></name></person-group><article-title>Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation</article-title><source>Proc Natl Acad Sci USA</source><year>1992</year><volume>89</volume><fpage>11059</fpage><lpage>11063</lpage><pub-id pub-id-type="pmid">1438315</pub-id></element-citation></ref><ref id="CVP001C87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeishi</surname><given-names>Y</given-names></name><name><surname>Ping</surname><given-names>P</given-names></name><name><surname>Bolli</surname><given-names>R</given-names></name><name><surname>Kirkpatrick</surname><given-names>DL</given-names></name><name><surname>Hoit</surname><given-names>BD</given-names></name><name><surname>Walsh</surname><given-names>RA</given-names></name></person-group><article-title>Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy</article-title><source>Circ Res</source><year>2000</year><volume>86</volume><fpage>1218</fpage><lpage>1223</lpage><pub-id pub-id-type="pmid">10864911</pub-id></element-citation></ref><ref id="CVP001C88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Windt</surname><given-names>LJ</given-names></name><name><surname>Lim</surname><given-names>HW</given-names></name><name><surname>Haq</surname><given-names>S</given-names></name><name><surname>Force</surname><given-names>T</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name></person-group><article-title>Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>13571</fpage><lpage>13579</lpage><pub-id pub-id-type="pmid">10788473</pub-id></element-citation></ref><ref id="CVP001C89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Bishop</surname><given-names>SP</given-names></name></person-group><article-title>Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat</article-title><source>Circ Res</source><year>1994</year><volume>75</volume><fpage>926</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">7923639</pub-id></element-citation></ref><ref id="CVP001C90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pass</surname><given-names>JM</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>WK</given-names></name><name><surname>Wead</surname><given-names>WB</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Enhanced PKC beta II translocation and PKC beta II-RACK1 interactions in PKC epsilon-induced heart failure: a role for RACK1</article-title><source>Am J Physiol</source><year>2001</year><volume>281</volume><fpage>H2500</fpage><lpage>H2510</lpage></element-citation></ref><ref id="CVP001C91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shizukuda</surname><given-names>Y</given-names></name><name><surname>Buttrick</surname><given-names>PM</given-names></name></person-group><article-title>Protein kinase C(epsilon) modulates apoptosis induced by beta -adrenergic stimulation in adult rat ventricular myocytes via extracellular signal-regulated kinase (ERK) activity</article-title><source>J Mol Cell Cardiol</source><year>2001</year><volume>33</volume><fpage>1791</fpage><lpage>1803</lpage><pub-id pub-id-type="pmid">11603922</pub-id></element-citation></ref><ref id="CVP001C92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>MU</given-names></name><name><surname>LaRosee</surname><given-names>P</given-names></name><name><surname>Schon</surname><given-names>S</given-names></name><name><surname>Borst</surname><given-names>MM</given-names></name><name><surname>Strasser</surname><given-names>RH</given-names></name></person-group><article-title>Differential regulation of cardiac protein kinase C isozyme expression after aortic banding in rat</article-title><source>Cardiovasc Res</source><year>2002</year><volume>56</volume><fpage>52</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">12237166</pub-id></element-citation></ref><ref id="CVP001C93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeishi</surname><given-names>Y</given-names></name><name><surname>Jalili</surname><given-names>T</given-names></name><name><surname>Ball</surname><given-names>NA</given-names></name><name><surname>Walsh</surname><given-names>RA</given-names></name></person-group><article-title>Responses of cardiac protein kinase C isoforms to distinct pathological stimuli are differentially regulated</article-title><source>Circ Res</source><year>1999</year><volume>85</volume><fpage>264</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">10436169</pub-id></element-citation></ref><ref id="CVP001C94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koide</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Kitamura</surname><given-names>K</given-names></name><name><surname>Yokoyama</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Differential induction of protein kinase C isoforms at the cardiac hypertrophy stage and congestive heart failure stage in Dahl salt-sensitive rats</article-title><source>Hypertens Res</source><year>2003</year><volume>26</volume><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">12887134</pub-id></element-citation></ref><ref id="CVP001C95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeishi</surname><given-names>Y</given-names></name><name><surname>Bhagwat</surname><given-names>A</given-names></name><name><surname>Ball</surname><given-names>NA</given-names></name><name><surname>Kirkpatrick</surname><given-names>DL</given-names></name><name><surname>Periasamy</surname><given-names>M</given-names></name><name><surname>Walsh</surname><given-names>RA</given-names></name></person-group><article-title>Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure</article-title><source>Am J Physiol</source><year>1999</year><volume>276</volume><fpage>H53</fpage><lpage>H62</lpage><pub-id pub-id-type="pmid">9887017</pub-id></element-citation></ref><ref id="CVP001C96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hambleton</surname><given-names>M</given-names></name><name><surname>York</surname><given-names>A</given-names></name><name><surname>Sargent</surname><given-names>MA</given-names></name><name><surname>Kaiser</surname><given-names>RA</given-names></name><name><surname>Lorenz</surname><given-names>JN</given-names></name><name><surname>Robbins</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inducible and myocyte-specific inhibition of PKCalpha enhances cardiac contractility and protects against infarction-induced heart failure</article-title><source>Am J Physiol</source><year>2007</year><volume>293</volume><fpage>H3768</fpage><lpage>H3771</lpage></element-citation></ref><ref id="CVP001C97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>ER</given-names></name><name><surname>Shamhart</surname><given-names>PE</given-names></name><name><surname>Naugle</surname><given-names>JE</given-names></name><name><surname>Meszaros</surname><given-names>JG</given-names></name></person-group><article-title>Angiotensin II-induced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase Cdelta and intracellular calcium in adult rat cardiac fibroblasts</article-title><source>Hypertension</source><year>2008</year><volume>51</volume><fpage>704</fpage><lpage>711</lpage><pub-id pub-id-type="pmid">18195168</pub-id></element-citation></ref><ref id="CVP001C98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husse</surname><given-names>B</given-names></name><name><surname>Briest</surname><given-names>W</given-names></name><name><surname>Homagk</surname><given-names>L</given-names></name><name><surname>Isenberg</surname><given-names>G</given-names></name><name><surname>Gekle</surname><given-names>M</given-names></name></person-group><article-title>Cyclical mechanical stretch modulates expression of collagen I and collagen III by PKC and tyrosine kinase in cardiac fibroblasts</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2007</year><volume>293</volume><fpage>R1898</fpage><lpage>R1907</lpage><pub-id pub-id-type="pmid">17686880</pub-id></element-citation></ref></ref-list></back></article>